TY - JOUR
T1 - Update on Combinations of DAAs With and Without Pegylated-Interferon and Ribavirin. Triple and Quadruple Therapy More Than Doubles SVR
AU - Martel-Laferrière, Valérie
AU - Dieterich, Douglas T.
PY - 2013/2
Y1 - 2013/2
N2 - Monotherapy is an ineffective way to treat hepatitis C and it leads to rapid development of resistance. An increasing number of drugs are currently being developed for the treatment of hepatitis C. This allows combination strategies that can overcome the development of resistance and improve sustained virologic response rates. This article focuses on the 2 main strategies in development: quadruple combination therapies, including pegylated-interferon and triple/quadruple pegylated-interferon free combination therapies. If the first combinations are leading to extremely high sustained virologic responses, the second ones offer hope that the era of pegylated-interferon will end soon.
AB - Monotherapy is an ineffective way to treat hepatitis C and it leads to rapid development of resistance. An increasing number of drugs are currently being developed for the treatment of hepatitis C. This allows combination strategies that can overcome the development of resistance and improve sustained virologic response rates. This article focuses on the 2 main strategies in development: quadruple combination therapies, including pegylated-interferon and triple/quadruple pegylated-interferon free combination therapies. If the first combinations are leading to extremely high sustained virologic responses, the second ones offer hope that the era of pegylated-interferon will end soon.
KW - Combination therapy
KW - Hepatitis C
KW - Monotherapy
KW - Pegylated-interferon free
UR - https://www.scopus.com/pages/publications/84870021615
U2 - 10.1016/j.cld.2012.09.001
DO - 10.1016/j.cld.2012.09.001
M3 - Review article
C2 - 23177285
AN - SCOPUS:84870021615
SN - 1089-3261
VL - 17
SP - 93
EP - 103
JO - Clinics in Liver Disease
JF - Clinics in Liver Disease
IS - 1
ER -